Ask AI
ProCE Banner Activity

Disease Modification in Alzheimer's Disease: Current Evidence, Clinical Practice, and Emerging Directions

Slideset

Advances in Alzheimer’s disease (AD) research are reshaping the understanding and clinical application of disease-modifying therapies. Review these slides to examine the evidence supporting amyloid-targeting monoclonal antibodies, including effects on cognitive and functional decline, long-term treatment outcomes, amyloid-related imaging abnormalities (ARIA), and practical considerations for patient selection and monitoring. The presentation also explores emerging therapeutic approaches targeting tau pathology and neuroinflammation, advances in fluid biomarkers, and evolving strategies for earlier intervention, treatment optimization, and combination therapy.

Released: October 22, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for a multidisciplinary audience of neurologists, psychiatrists, primary care physicians, nurses, nurse practitioners, physician associates, pharmacists, and other members of the healthcare team involved in the management of patients with Alzheimer's Disease.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret clinical trial evidence for amyloid-targeting therapies in Alzheimer's disease, including their effects on cognitive and functional decline and the limitations of available efficacy data

  • Apply patient selection, risk stratification, and safety monitoring considerations to the use of amyloid-targeting therapies in patients with early Alzheimer's disease

  • Evaluate the mechanisms and available evidence for emerging disease-modifying strategies in Alzheimer's disease, including novel amyloid-targeting approaches, tau-directed therapies, and neuroinflammatory targets

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.